Risk Factors for Diabetic Peripheral Neuropathy and Cardiovascular Autonomic Neuropathy in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study demonstrated that intensive glucose control reduced the risk of developing diabetic peripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN). We evaluated multiple risk factors and phenotypes associated with DPN and CAN in this large, well-characterized cohort of participants with type 1 diabetes, followed for >23 years. DPN was defined by symptoms, signs, and nerve conduction study abnormalities in ≥2 nerves; CAN was assessed using standardized cardiovascular reflex tests. Generalized estimating equation models assessed the association of DPN and CAN with individual risk factors measured repeatedly. During DCCT/EDIC, 33% of participants developed DPN and 44% CAN. Higher mean HbA1c was the most significant risk factor for DPN, followed by older age, longer duration, greater height, macroalbuminuria, higher mean pulse rate, β-blocker use, and sustained albuminuria. The most significant risk factor for CAN was older age, followed by higher mean HbA1c, sustained albuminuria, longer duration of type 1 diabetes, higher mean pulse rate, higher mean systolic blood pressure, β-blocker use, estimated glomerular filtration rate <60 mL/min/1.73 m2, higher most recent pulse rate, and cigarette smoking. These findings identify risk factors and phenotypes of participants with diabetic neuropathy that can be used in the design of new interventional trials and for personalized approaches to neuropathy prevention.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, persons who fail to return for continued anti-VEGF treatments are at risk of losing vision.537,538”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [538]
In the citing paper
“The prevalence of and risk factors for standard resting ECG-derived CAN were similar to previously reported estimates from CARTs.”
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423 · cited 1×
“LDL cholesterol was calculated using the Friedewald equation (17).”
Method(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationInternational Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418 · cited 1×
“Although evidence for the benefit of b-blockers in modulating the impaired cardiac autonomic regulation during high sympathetic stress advocates for their use in patients with heart failure and/or post myocardial infarction (38), these agents are not currently recommended for the treatment of CAN (1).”
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 2×
“Although evidence for the benefit of b-blockers in modulating the impaired cardiac autonomic regulation during high sympathetic stress advocates for their use in patients with heart failure and/or post myocardial infarction (38), these agents are not currently recommended for the treatment of CAN (1).”
BackgroundSelf-citationPrevalence of Type 1 and Type 2 Diabetes Among Children and Adolescents From 2001 to 2009
Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., Bell, R., Badaru, A., Talton, J. W., Crume, T., et al. (2014) · JAMA · doi:10.1001/jama.2014.3201 · Cited by 1,412
Vascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915 · cited 1×
“The mechanisms linking hypertension to DPN are unclear but may involve a complex set of pathways interlinking nerve function and energy production with a dysfunctional neural vascular supply (29).”
BackgroundSelf-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.04.014 · Cited by 770
Research works printed but not linked: 1
- International Diabetes Federation. IDF Diabetes Atlas, 9th edition [Internet], 2019. Available from https://diabetesatlas.org
Cited by
Items 101–200 of 221
Yu, Z., Zhao, S., Cao, J., & Xie, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1477570 · Cited by 6
Diabetic small fiber neuropathy: clinical and electrophysiological study
Alkotami, A. S., Elkholy, S. H., Elshamy, A. M., El-Seidy, E. A. S., & Fadel, W. A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00923-8 · Cited by 7
Lee, S. J., Kim, C. H., Jeong, S. J., Yun, J., Won, J. C., Lee, J. H., Park, I. B., Lee, C. W., Kwon, H., & Park, T. S. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e154 · Cited by 9
Yang, J., Li, L., Ye, T., Pu, Y., Yao, Q., Luo, J., Huang, Y., Zhang, X., & Yang, Z. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1610955 · Cited by 10
Babu, D. D., Mehdi, S., Krishna, K. L., Lalitha, M. S., Someshwara, C. K., Pathak, S., Pesaladinne, U. R., Rajashekarappa, R. K., & Mylaralinga, P. S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01447-x · Cited by 6
“…of diabetes : Diabetic patients having the disorder for greater than 10 years have an increased possibility of developing diabetic neuropathy [16, 17]. h. Lifestyle and environmental factors : Sedentary life-style, obesity, smoking, alcohol consumption, diet rich in fat and sugar, stress,…”
Iwamoto, Y., Nakanishi, S., Komi, M., Kimura, Y., Watanabe, Y. S., Sasaki, T., Nakao, E., Kubo, M., Sugisaki, T., Dan, K., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0397 · Cited by 6
“Large clinical studies have shown that good long-term glycemic control can prevent the onset and progression of diabetic neuropathy [12, 13].”
de Silva, N. L., Athukorala, T., Gamage, J. L., Katulanda, G. W., de Silva, P., Sumanatilleke, M., & Somasundaram, N. P. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01108-1 · Cited by 25
Guo, N., Shi, H., Zhao, H., Abuduani, Y., Chen, D., Chen, X. F., Wang, H., & Li, P. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1381322 · Cited by 8
Menduni, M., D’Amato, C., Leoni, M., Izzo, V., Staltari, M., Greco, C., Abbatepassero, A., Seminara, G., D’Ippolito, I., Lauro, D., et al. (2022) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12510 · Cited by 10
“The components of the present CAN risk score are recognized clinical correlates of CAN in type 1 diabetes as microangiopathic and macrovascular complications,(22-28) or risk factors as HbA1c(24,28,29) and BP in longitudinal studies,(22,24,28,29) risk markers as HDL cholesterol in cross-sectional studies,(23,30) and sm…”
BackgroundBraffett, B. H., El ghormli, L., Martin, C., White, N. H., Hirsch, I. B., Bantle, A., Carlson, A., Leschek, E., Gubitosi-Klug, R., Soliman, E. Z., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02856-9 · Cited by 5
“This included CAN, defined during DCCT by CARTs as either an R-R variation during deep breathing < 15 or an R-R variation 15–19.9 in combination with a Valsalva ratio ≤ 1.5 or a decrease of > 10 mmHg in diastolic blood pressure upon and while standing for 10 min [3–5].”
InfluentialSelf-citationFrom bench to bedside: therapeutic potential of natural antioxidants in diabetic neuropathy
Zhang, Y., Yao, L., Lyu, Y., Tang, Z., Liu, X., & Duan, X. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1631678 · Cited by 8
Prevention of Peripheral Distal Polyneuropathy in Patients with Diabetes: A Systematic Review
Carvajal-Moreno, L., Coheña‐Jiménez, M., García-Ventura, I., Pabón‐Carrasco, M., & Belloso, A. J. P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061723 · Cited by 8
“…et al., 2018 [45] O’Brien et al., 2018 [46] Yang et al., 2020 [47] Cárdenas et al., 2019 [48] Cohort studies that do not specifically address the prevention of DPN, but from RCTs Aroda et al., 2016 [49] Gaede et al., 2016 [50] Abraham et al., 2018 [51] Braffett et al., 2020 [52] Figure 1.”
BackgroundKuchmerovska, T. M., Tykhonenko, T., Yanitska, L. V., Savosko, S. I., & Pryvrotska, I. B. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04257-y · Cited by 5
“Both types are characterized by hyperglycemia and dyslipidemia, which are major risk factors for developing microvascular and macrovascular complications, as well as neurological impairments [5].”
Ekın, M. A., Kahraman, H. G., Eğrilmez, E. D., Arıcı, Ş., & Örük, G. G. (2025) · International Ophthalmology · doi:10.1007/s10792-025-03420-w · Cited by 5
“Although the disease can involve both central and peripheral nerves, particularly DPN has been shown to affect around 33% of patients with type 1 DM after 23 years of follow-up [3].”
Zhang, Z., Huang, Z., Xi, Y., Han, S., Ye, X., Zhu, H., Guo, C., Liu, Z., & Guo, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16414 · Cited by 5
“5,6 Nearly 60% of those with uncontrolled T2D are expected to develop diabetic retinopathy within the first decade after diagnosis.”
Diabetic autonomic neuropathy is a barrier to achieving glycemic control
Verbovoy, A. F., & Sharonova, L. A. (2020) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2020-4-144-151 · Cited by 5
Preventing diabetes-related foot ulcers through early detection of peripheral neuropathy
McMorrow, R., Nubé, V. L., & Manski-Nankervis, J.-A. E. (2022) · Australian Journal of General Practice · doi:10.31128/ajgp-06-22-6456 · Cited by 12
Li, X., Cheng, L., Jiang, T., Liu, C., Zhang, S., Hu, H., Dai, F., Zhang, Q., & Lu, Y. (2021) · Journal of International Medical Research · doi:10.1177/03000605211051225 · Cited by 8
“The risk factors identified using principal components analysis fit well with the natural history of patients with DM-CKD.”
BackgroundInfluentialAnumah, F. E., Lawal, Y., Reng, R. S., Omonua, O. S., Odumodu, K., Shuaibu, R., Itanyi, U. D., Abubakar, A. I., Kolade-Yunusa, H. O., David, Z. S., et al. (2023) · The Foot · doi:10.1016/j.foot.2023.101987 · Cited by 5
Bergdahl, E., Forsander, G., Milkovic, L., Sundberg, F., & Dangardt, F. (2025) · Diabetologia · doi:10.1007/s00125-025-06592-3 · Cited by 4
“[9–11] associated with type 1 diabetes duration, hypertension and diabetic kidney disease (DKD) [9, 10, 12].”
The association between smoking and diabetic neuropathy: a systematic review and meta-analysis
Bader, S., Hasan, S., Magliano, D. J., Islam, R. M., Palawaththa, S., Romero, L., & Karim, M. N. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02995-w · Cited by 6
“A total of 75 studies were included in the meta-analysis, consisting of 228,699 participants, with diabetes mellitus (type 1 or type 2) constituting 54 cross-sectional studies [9, 22, 29–80], 8 case–control studies [81–88], and 13 cohort studies [21, 89–100].”
Yang, S., Lin, Y., Liao, X., Chen, J.-J., & Wu, H. (2025) · Journal of Applied Biomedicine · doi:10.1016/j.bbe.2025.08.006 · Cited by 4
Shan, X., Yao, S., Hu, B., Xu, C., Cao, Y., & Dai, W. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s526784 · Cited by 5
Szwergold, B. S. (2021) · Rejuvenation Research · doi:10.1089/rej.2021.0009 · Cited by 6
A Systematic Review on Extracting Predictors for Forecasting Complications of Diabetes Mellitus
Erandathi, M., Wang, W. Y. C., & Mayo, M. (2021) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3472813.3473211 · Cited by 6
Lindholm, E., Ekman, L., Elgzyri, T., Lindholm, B., Löndahl, M., & Dahlin, L. B. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2010-6987 · Cited by 4
“In the DCCT/EDIC study, 33 % of the patients developed peripheral diabetic neuropathy [10].”
BackgroundYang, Y., Liu, L., Wang, H. H., Lu, Y., Li, J., Liu, P., Hu, Z., & Yang, X. Q. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112847 · Cited by 4
“An elevated level of HbA1c has been identified as the most significant risk factor for DPN, with an odds ratio (OR) of 1.63 and a 95 % CI ranging from 1.51 to 1.77 (Braffett et al., 2020).”
InfluentialKlowak, M., Lau, R., Mohammed, M., Birago, A., Samson, B., Ahmed, L., Renee, C., Meconnen, M., Bado, E., Reid-John, A., et al. (2025) · NeuroSci · doi:10.3390/neurosci6030074 · Cited by 3
“Most cohort studies focused on populations with peripheral neuropathy (PN) (n = 6) [26,27,30,35–37], or broadly defined neuropathy (n = 5) [25,28,31,33,34], with fewer examining pain (n = 1) [25] and complex regional pain syndrome (CRPS) (n = 1) [32].”
Machine learning models predict mortality risk in diabetic neuropathy patients using MIMIC-IV data
Huang, Y., Mo, W., Liu, Y., Wang, S., Zeng, Y., Jiang, P., Wang, H., & Bi, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-22363-x · Cited by 4
“…age, duration of diabetes, HbA1c, fasting blood glucose (FBG), High triglyceride (HTG), total cholesterol (TC), hypertension, urine protein concentration, Diabetic retinopathy (DR), Diabetic kidney disease (DKD), and Cardiovascular diseases (CVD), can be used to predict the risk of DN 11–15 .”
Thermosensitive Hydrogel for Controlled Delivery of PAD4 Inhibitor YJ-2 in Diabetic Wound Healing
Wang, K., Taledaohan, A., Chan, L., Lu, Y., Jia, Y., & Wang, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010135 · Cited by 4
“However, in diabetic patients, thickening of the basement membranes in capillaries and arterioles restricts blood flow, thereby disrupting the physiological healing cascade [4,5].”
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 4
Gupta, P., Doherty, L., Temprosa, M. G., Pop‐Busui, R., Gadde, K. M., Singh, P., Owora, A. H., Wessells, H., & Sarma, A. V. (2024) · Neurourology and Urodynamics · doi:10.1002/nau.25436 · Cited by 4
“As a higher resting heart rate has been suggested as an indirect measure of CAN; 34,35 these findings are in contrast to others that have proposed a role for autonomic neuropathy in the development of FSD 36 including our prior reports in T1D.”
ResultSelf-citationHuang, X., Bao, Y., Wang, J., & Tian, L. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507244 · Cited by 5
“Several interrelated functional changes, such as inflammation [29], endothelial dysfunction [22], leptin dysfunction [30], and gastric hunger hormone regulation [31], may lead to increased sympathetic neural activity, decreased cardiac stress reflex sensitivity, and promote CAN development [32].”
BackgroundLawal, Y., Reng, R. S., Omonua, O. S., Odumodu, K., Shuaibu, R., Itanyi, U. D., Abubakar, A. I., Kolade-Yunusa, H. O., David, Z. S., Ogunlana, B., et al. (2025) · Journal of the American Podiatric Medical Association · doi:10.7547/l22-053 · Cited by 3
Bakre, S., Holt, S. K., Oerline, M., Braffett, B. H., Pop‐Busui, R., Wessells, H., & Sarma, A. V. (2021) · Neurourology and Urodynamics · doi:10.1002/nau.24823 · Cited by 3
Self-citationWang, J., Xu, Z., Lv, K., Ye, Y., Luo, D., Wan, L., Zhou, F., Yu, A., Wang, S., Liu, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.864008 · Cited by 5
Kang, S. M., Hong, J. H., & Ku, B. J. (2023) · Medicine · doi:10.1097/md.0000000000033701 · Cited by 3
Perfil social e clínico de crianças e adolescentes com diabetes mellitus tipo 1
Cavalcante, M. E. P. L., Ramalho, E. L. R., Pessoa, M. S. D. A., Oliveira, R. C., Sparapani, V. D. C., Nascimento, L. C., & Collet, N. (2023) · Revista de Enfermagem da UFSM · doi:10.5902/2179769272186 · Cited by 10
Xiong, F., Wang, Q., Hu, Y., Jiang, X., Liu, L., Han, Y., Jiang, Q. Y., Yuan, S., & Xu, L. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0056 · Cited by 9
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)
Ren, Q., Fan, Y., Yang, L., Shan, M., Shi, W., & Qian, H. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2272649 · Cited by 3
“Uncontrolled diabetes could lead to various complications, including diabetic nephropathy [4], diabetic eye complications [5], diabetic cardiovascular complications [6], diabetic foot [7], and diabetic neuropathy.”
BackgroundComprehensive Factors for Predicting the Complications of Diabetes Mellitus: A Systematic Review
Erandathi, M., Wang, W. Y. C., Mayo, M., & Lee, C. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271863231116062601 · Cited by 8
“However, the lipid profile of patients is not highly associated with gender [3].”
BackgroundInfluentialYu, Z., Yang, J., Jiang, Y., Wei, M., Lyu, Y., Yang, D., Shen, S., Han, Y., & Li, M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01376-x · Cited by 4
Zhao, Q., Wang, J., Liu, F., Jiang, H., & Ma, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1496635 · Cited by 5
“A meta-analysis of risk factors for DPN showed that diabetes duration, age, HbA1c levels, and diabetic retinopathy (DR) were signi fi cantly associated with an increased risk of DPN (28).”
T1DMicro: A Clinical Risk Calculator for Type 1 Diabetes Related Microvascular Complications
Tran, P. M. H., Kim, E., Tran, L. K. H., Satter, K. B., Zhi, W., Bai, S., Hopkins, D., Gardiner, M., Bryant, J., Bernard, R., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111094 · Cited by 4
Early Detection of Diabetic Peripheral Neuropathy in Diabetic Patients: A Cross-Sectional Study
Amelia, R., Wahyuni, A. S., Yunanda, Y., Fujiati, I. I., Harahap, J., Wijaya, H., Zulham, Z., & Saktioto, S. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998297210240325062747 · Cited by 4
Azhari, H. F., & Dawson, J. (2024) · Frontiers in Stroke · doi:10.3389/fstro.2024.1363954 · Cited by 4
Assessing Autonomic Dysfunction in Diabetes: A Hospital-based Study in a Developing Country
Dafalla, K. A., Alawad, A. O., Merghani, T. H., Ahmed, F. M., & Ebraheem, A. A. (2025) · Annals of African Medicine · doi:10.4103/aam.aam_202_24 · Cited by 4
“[2,4] The presence of these risk factors may accelerate the progression of CAN and highlight the need for early screening and intervention.”
Vania, A., Samatra, D. P. G. P., Adnyana, I. M. O., Saraswati, M. R., Darwinata, A. E., & Widyadharma, I. P. E. (2025) · Journal of Neurogenetics · doi:10.1080/01677063.2025.2473705 · Cited by 2
“Further studies are needed to investigate insulin therapy as a risk factor for PDN, as other studies have also reported that insulin therapy is associated with an increased risk of PDN (Braffett et al ., 2020; Pai et al ., 2018).”
Lee, C., Lai, C.-W., Wu, G.-L., Yen, S., Huang, C., Liu, Z.-H., Hu, P.-C., & Liao, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1621448 · Cited by 2
Pathogenesis and Treatment of Diabetic Peripheral Neuropathy
Kang, S. M. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.4.222 · Cited by 2
“또한 젊은 당뇨병 전단계에 있는 환자에서도 발생한다고 알려져 있어 당뇨병환 자가 평생 당뇨병신경병증에 이환될 확률은 50%가 넘는 것 으로 알려져 있다[3-5].”
Kazemzadeh, K., Bayani, M., Khademi, R., Sadatmadani, S. F., Habibzadeh, A., Shirani, M., Ghadri, H., Abbasalizadeh, M., Izadi, E., Rezaee, M., et al. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01359-2 · Cited by 2
Diabetic Polyneuropathy: from Pathogenesis to Pathogenetic Therapy
Tanashyan, M. М., State, F. S. A. E. I. O. H. E. ‘. M. S. F. M., Антонова, К. В., Спрышков, Н. Е., Панина, А. А., Лагода, О. В., & Shchukina, E. P. (2024) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2024-20-8-54-62 · Cited by 3
SLOAN, G. P., Pena, P. D., Andag‐Silva, A., Cunanan, E. C., Jimeno, C., Robles, J. J., & Tesfaye, S. H. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14268 · Cited by 2
“However, when sensitive tests are used, such as nerve conduction studies, the reported prevalence is closer to 50% 24 – 26 .”
MethodMairaj, M., Pala, N. A., & Ismail, M. (2024) · Cureus · doi:10.7759/cureus.73304 · Cited by 2
El-Deen, A. E.-S. N., shallaby, A., Ibrahim, A. K., Mohammed, M. A. A., Taha, A., Hafez, M. Z., Elfiky, M. A. H., El-Rhman, A. A. A., Ghany, A. F. A., Elsayed, A. M., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2024.e41607 · Cited by 2
Chander, K. (2021) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20211916 · Cited by 2
Lakshmi, L. J., Rathore, S., Faizal, M., Yusuf, F. N. K., & Doddigarla, Z. (2022) · Indian Journal Of Applied Research · doi:10.36106/ijar/9801433 · Cited by 2
Bashar, M. (2020) · Research Square · doi:10.21203/rs.3.rs-59734/v1 · Cited by 2
“This was similar to ndings from other studies [14],[15].”
ResultInfluentialDiabetic neuropathy: Current issues in diagnosis and prevention
Spallone, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00016-6 · Cited by 2
Assessment of healthcare utilization in diabetes patients according to foot risk level
Fernández, C. B., Gracia‐Sánchez, A., Zúnica‐García, S., & Chicharro‐Luna, E. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.12.005 · Cited by 1
Aguiar, C. H., Pedrosa, H. C., Tannus, L. R. M., Ferreira, L. L., Da, S., Pôrto, L. C., Negrato, C. A., & Gomes, M. B. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70049 · Cited by 2
Migdalis, I. N., Tentolouris, N., Didangelos, T., Παπάνας, Ν., Bristianou, M., Mavrogiannaki, A. N., & Study, O. B. O. T. P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196723 · Cited by 4
“Chronic hyperglycemia is a central driver, activating the polyol and protein kinase C pathways and promoting the accumulation of advanced glycation end products, which trigger oxidative stress and neuronal injury [12,17–19].”
Pop‐Busui, R., Rosin, S. P., Butera, N. M., Krause-Steinrauf, H. J., Assi, H. A., Garg, R., Inzucchi, S. E., Katona, A. M., McGill, J. B., Mudaliar, S. R. D., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1087 · Cited by 2
Self-citationRubin, M. R., Kazakia, G. J., Braffett, B. H., Gregory, N. S., Lin, M., Trapani, V. R., de Boer, I. H., Agarwal, S., Burghardt, A. J., Guo, X.-D. E., et al. (2025) · JBMR Plus · doi:10.1093/jbmrpl/ziaf167 · Cited by 1
Self-citationPeng, J., Xue, D., Li, J., Wei, L., & Wang, Y. (2026) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s573535 · Cited by 1
“47,48 Based on these findings, comprehensive interventions targeting these modifiable behavioral factors are recommended.”
Zhang, Q., Wang, H., Sun, M., Wu, Y., & Xie, P. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70259 · Cited by 1
“The later peak re fl ects the cumulative effect of extended diabetes duration and acquired comorbidities such as hypertension, dyslipidemia, and obesity 37 .”
Lin, Q., Zhou, Y., LEI, M., Ling, P., NI, Y., Lin, Z., Yang, D., Xu, W., Deng, H., & Yan, J. (2026) · Diabetic Medicine · doi:10.1111/dme.70354 · Cited by 1
“…at least 5% and achieving the consensus target have been reported to be associated with a meaningful reduction in diabetes-related complications, 28,29 these findings further underscore the potential benefits of AID systems in very young children with T1D—a population facing a lifetime of insulin…”
Mocanu, C. A., Salmen, T., Chitu, M.-C., Cîmpeanu, R.-C., Clus, S., Reurean‐Pintilei, D., Stoian, A. P., & Serafinceanu, C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103976 · Cited by 3
“Observational studies have reported independent associations between adverse lipid profiles and DPN prevalence or severity, even after adjustment for glycemic indices [11–13].”
Savelieff, M. G., Bennett, D., Jensen, T. S., & Feldman, E. L. (2026) · Annals of Neurology · doi:10.1002/ana.78289 · Cited by 1
“28 In contrast, DD2 18 and DCCT/EDIC 15 linked reduced HDL-c to higher PN prevalence ratio or risk after adjusting for diabetes duration or HbA1c, as well as age.”
InfluentialSelf-citationLyon, M. M. (2021) · Physician Assistant Clinics · doi:10.1016/j.cpha.2021.07.002 · Cited by 3
Treatment of diabetic polyneuropathy
Peltier, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00021-9 · Cited by 2
Zhang, L., Guo, K., Xu, Y., Bai, J., Ma, Y., Fu, L., Liu, J., Hu, K., Li, X., Jiang, H., et al. (2022) · PubMed Central · doi:10.11817/j.issn.1672-7347.2022.210524 · Cited by 1
Neuropathy in Type 1 and Type 2 Diabetes
Akıncı, G., Nowacek, D. G., & Callaghan, B. C. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_4 · Cited by 1
Bashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Intelligenza Artificiale per la cura del diabete mellito: opportunità e prospettive future
(2024) · il Diabete · doi:10.30682/ildia2304g · Cited by 1
Diabetic foot and surgical treatment
Vučetić, Č. (2023) · Galenika Medical Journal · doi:10.5937/galmed2308035v · Cited by 1
Prevalence of neuropathy in type 2 diabetic patients at sub-district hospital Akhnoor
Sharma, C., & Badyal, A. (2021) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20211445 · Cited by 1
Šumník, Z., Konečná, P., Venháčová, P., Neumann, D., Škvor, J., Pomahačová, R., Strnadel, J., Průhová, Š., Petruželková, L., Vosáhlo, J., et al. (2022) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2022/008 · Cited by 1
Helmy, N. M., Aly, A. A., Awad, W. H. A., Younes, M. M. A. E., & Almanzlawi, H. A. I. (2022) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2022.273891 · Cited by 1
A dohányzás szerepe a cukorbetegség és szövődményeinek kialakulásában
Körei, A. E., Putz, Z., Istenes, I., Tordai, D. Z., Hajdú, N., Békeffy, M. Z., Vági, O. E., & Kempler, P. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.18
Majumdar, M., Banerjee, M., Sengupta, J., Deb, S., Jana, C. K., & Roy, B. K. (2020) · medRxiv · doi:10.1101/2020.04.12.20056150 · Cited by 1
Cardiovascular Autonomic Neuropathy
Ang, L. P., & Pop‐Busui, R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_12 · Cited by 2
Self-citationLi, Z., Jian, Y., Deng, C., & Wei, Z. (2025) · Research Square · doi:10.21203/rs.3.rs-6637207/v1 · Cited by 1
Alter, Rauchen, HbA1c und Nierenfunktion prägen Amputationsrisiko bei Typ-1-Diabetes
Spraul, M. (2021) · Info Diabetologie · doi:10.1007/s15034-021-3767-0
Колбин, А. С., Kurylev, A. A., Balykina, Y. Е., & Proskurin, M. A. (2022) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2022-1-4-16 · Cited by 1
Prevention of Major Amputation secondary to Diabetes-related Foot Disease
Hayes, J. M. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60123
Tian, Z., Fan, Y., Sun, X., Wang, D., Guan, Y., Zhang, Y., Zhang, Z., Guo, J., Bu, H., Wu, Z., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2096555/v1
Risk Factors Associated with Cardiac Autonomic Neuropathy in Type 1 Diabetes Mellitus
Amadea, M. A., Hariyanto, D., & Rini, E. A. (2023) · International Journal of Research and Review · doi:10.52403/ijrr.20230649
The role of glycemic control in the development of late complications of diabetes mellitus
Bulgakova, S. V., Kosareva, O. V., Dolgikh, Y. A., Sharonova, L. A., & Mamedova, A. G. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-461
Transitioning Adolescents and Young Adults with Type 1 Diabetes to Adulthood
D’Amico, R., & Buschur, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-54281-7_29
Kanthed, P., Barasker, S. K., & Ravikumar, C. M. (2024) · Indian Journal of Pain · doi:10.4103/ijpn.ijpn_119_23
Baldimtsi, E. (2024) · Linköping University medical dissertations · doi:10.3384/9789180756662
The Effect of L-NAME and Celecoxib on Diabetic Neuropathy in Rats
Hosseini, M., Karimi, S., Heydari, A., Banafshe, H. R., Alavi, S. S., Hadizadeh, M., & Hamidi, G. A. (2025) · Majallah-i dānishgāh-i ̒ulum-i pizishkī-i Kirmān. · doi:10.34172/jkmu.3195
Barros, C. L., de Oliveira-Junior, S. A., Amato, A. A., Santana, L. D. Á., & Carregaro, R. L. (2025) · Physiotherapy Practice and Research · doi:10.1177/22130683251337313
Saienko, Y. A., & Mankovsky, B. (2025) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.21.3.2025.1173
MODERN ASPECTS OF THE TREATMENT OF PAINFUL DIABETIC NEUROPATHY USING NEW GABAPENTINOID MIROGABALIN
Karachentsev, Y. I., Кравчун, Н. А., & Кравчун, П. П. (2025) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2025.2.08
Somisetty, K. G., Shetty, G. B., Sujatha, K. J., & Shetty, P. (2025) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2025.101147 · Cited by 1
“DPN is the most challenging chronic complication given the independent risk for lower limb amputations, severe pain, falls and fractures, and direct impact on daily function and quality of life [5].”
Kyryk, K. A., Подолюк, М. В., Hresko, N. I., Mykhalevych, M. M., Logash, M. V., & Бекесевич, А. М. (2025) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2025-2-177-429-437
Painful diabetic polyneuropathy in patients with cerebrovascular diseases
Tanashyan, M. М., Антонова, К. В., & Панина, А. А. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512507164
Zeb, M. J. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf150
Metadata
- Authors
- Braffett, B. H., Gubitosi-Klug, R. A., Albers, J. W., Feldman, E. L., Martin, C. L., White, N. H., Orchard, T. J., Lopes-Virella, M., Lachin, J. M., Pop-Busui, R., & the DCCT/EDIC Research Group
- Affiliations
- George Washington University (US)
- Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland, OH
- University of Michigan (US)
- Washington University in St. Louis (US)
- University of Pittsburgh (US)
- Medical University of South Carolina (US)
- University of Michigan Medical School, Ann Arbor, MI
- Corresponding author
- Braffett, Barbara H.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-02-12
- Volume
- 69
- Issue
- 5
- Pages
- 1000-1010
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC7171957
- OpenAlex
- W3006227931
- Cited by
- 221
- References
- 40
- Citations by year
- 2026: 26 · 2025: 41 · 2024: 45 · 2023: 31 · 2022: 40 · 2021: 24 · 2020: 14
- FWCI
- 20.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01dk094157-13, UL1TR002345)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK094176, U01-DK094157, P30DK092926, P30DK020572, P30DK017047)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- diabetic peripheral neuropathy, cardiac autonomic neuropathy, type 1 diabetes, risk factors, tight glycemic control, HbA1c, albuminuria, macroalbuminuria, beta-blocker use, pulse rate, cigarette smoking, neuropathy prevention, DCCT/EDIC
- MeSH terms
- Adult, Autonomic Nervous System, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Female, Glycated Hemoglobin, Humans, Longitudinal Studies, Male, Risk Factors, Cohort Studies, Multivariate Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.